Literature DB >> 7617123

Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis.

T J Tsai1, R H Lin, C C Chang, Y M Chen, C F Chen, F N Ko, C M Teng.   

Abstract

Mesangial cell activation and extracellular matrix accumulation are hallmarks of many forms of glomerulonephropathy. We investigated the effect of several agents possessing vasodilating activities on rat mesangial cell growth and collagen synthesis. Using cell counting and a modified MTT assay, it was shown that dipyridamole, pentoxifylline, dicentrine, prazosin and doxazosin all caused a dose-dependent inhibition of serum-stimulated rat mesangial cell proliferation. Platelet-derived growth factor-induced cell proliferation was also inhibited by doxazosin and pentoxifylline. Dipyridamole and pentoxifylline inhibited collagen synthesis in confluent mesangial cells while dicentrine and doxazosin did not. The procollagen alpha 1 (I) mRNA expression was also decreased by dipyridamole and pentoxifylline. These results suggested that, in addition to dipyridamole, pentoxifylline and alpha 1-adrenoceptor blockers may have a potential to delay the progression of chronic glomerulopathy associated with mesangial proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617123     DOI: 10.1159/000188550

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.

Authors:  Kum Hyun Han; Sang Youb Han; Han Seong Kim; Young Sun Kang; Dae Ryong Cha
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

Review 2.  Molecular targets for treatment of kidney fibrosis.

Authors:  Peter Y Chuang; Madhav C Menon; John C He
Journal:  J Mol Med (Berl)       Date:  2012-11-22       Impact factor: 4.599

3.  Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial.

Authors:  Shahrzad Shahidi; Marziyeh Hoseinbalam; Bijan Iraj; Mojtaba Akbari
Journal:  Int J Nephrol       Date:  2015-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.